Jangra, Rohit K.
Herbert, Andrew S.
Li, Rong
Jae, Lucas T.
Kleinfelter, Lara M.
Slough, Megan M.
Barker, Sarah L.
Guardado-Calvo, Pablo
Román-Sosa, Gleyder
Dieterle, M. Eugenia
Kuehne, Ana I.
Muena, Nicolás A.
Wirchnianski, Ariel S.
Nyakatura, Elisabeth K.
Fels, J. Maximilian
Ng, Melinda
Mittler, Eva
Pan, James
Bharrhan, Sushma
Wec, Anna Z.
Lai, Jonathan R.
Sidhu, Sachdev S.
Tischler, Nicole D.
Rey, Félix A.
Moffat, Jason
Brummelkamp, Thijn R.
Wang, Zhongde
Dye, John M.
Chandran, Kartik
Article History
Received: 22 February 2018
Accepted: 20 September 2018
First Online: 21 November 2018
Competing interests
: R.K.J., L.T.J., K.C. and T.R.B. are named inventors on US patent application US20170173141A1, covering methods to treat hantavirus infections by targeting PCDH1 (the entry factor described here), the application being assigned to Albert Einstein College of Medicine. T.R.B. is co-founder and Scientific Advisory Board member of Haplogen GmbH, and co-founder and managing director of Scenic Biotech BV. F.A.R. is a consultant for Flagship Pioneering.